Health TechSyneron Bio Secures $150M Series B, Doubling Down on Peptide Drug Discovery Ambitions
Syneron Bio has raised $150M in a Series B round just four months after its $100M Series A, signaling surging investor confidence in peptide therapeutics and next-gen drug discovery platforms.






